Our academic founders have played a key role in demonstrating that senescence occurs in response to cellular damage and that senescence occurs in vivo in normal and pathological settings.
The science is based on our unique ability to design and develop strategies that selectively target and eliminate damaged cells from tissues where they drive disease progression.
Founders have published key academic papers in the field.
SEN01 - Targeted drug (IPF-Cancer)The accumulation of Cellular senescence worsens the severity of several fibrotic pathologies. The SEN01 program aims to develop senolytic compounds that target and eliminate senescent cells in fibrotic diseases and certain cancers.SEN02 - Immunotherapy (Oncology)The discovery program SEN02 is focused on immune system-mediated clearance of damaged cells to improve post-oncological treatment.SEN03 - Discovery platformWe are in the process to discover novel senolytic compounds in collaboration with other companies and research organizations.
A "Life Biosciences" company.